Burlingame, CA, United States of America

Jacqueline Walling


Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2002-2004

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jacqueline Walling

Introduction

Jacqueline Walling is a notable inventor based in Burlingame, CA (US). She has made significant contributions to the field of medicine, particularly in the development of combination therapies for treating proliferative disorders. With a total of 2 patents, her work is recognized for its potential impact on cancer treatment.

Latest Patents

Walling's latest patents include innovative therapies that utilize pentafluorobenzenesulfonamides. The first patent focuses on a combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents, such as gemcitabine or paclitaxel. This therapy aims to enhance treatment efficacy for patients suffering from proliferative disorders. The second patent also revolves around combination therapies, specifically using pentafluorobenzenesulfonamides in conjunction with antineoplastic platinum coordination complexes like cisplatin. These advancements highlight her commitment to improving therapeutic options in oncology.

Career Highlights

Jacqueline Walling has established herself as a key figure in her field through her innovative research and development efforts. Her work at Tularik Limited has allowed her to collaborate with other talented professionals and contribute to groundbreaking medical advancements.

Collaborations

Walling has worked alongside esteemed colleagues, including Susan Schwendner and Pieter Timmermans. These collaborations have fostered an environment of innovation and creativity, further enhancing the impact of her work.

Conclusion

Jacqueline Walling's contributions to the field of medicine through her patents and collaborative efforts exemplify her dedication to advancing cancer treatment. Her innovative approaches continue to inspire and pave the way for future research in combination therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…